E
Palisade Bio, Inc. PALI
$0.7556 -$0.0207-2.67% NASDAQ
Recommendation
Prev Close
$0.7763
Volume
24,194
Avg Vol (90D)
437,637
Market Cap
$3.41M
Dividend & Yield
--
52-Week Range
$0.60 - $9.09
P/E (TTM)
--
EPS (TTM)
-$11.78
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108 ...
4/9/2025 - GuruFocus
Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108
4/9/2025 - GuruFocus
Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108
4/9/2025 - Globe Newswire
Maxim Group Sticks to Their Buy Rating for Palisade Bio (PALI)
3/26/2025 - TipRanks Financial Blog
Palisade Bio (NASDAQ:PALI) Posts Quarterly Earnings Results, Beats Expectations By $1.70 EPS
3/25/2025 - Ticker Report
Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Up 38.4% in February
3/16/2025 - Ticker Report
Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b ...
3/14/2025 - GuruFocus
Palisade Bio commences dosing in first UC patient cohort in study of PALI-2108
3/14/2025 - The Fly
Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108
3/14/2025 - Globe Newswire
Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and ...
3/12/2025 - GuruFocus
Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025
3/12/2025 - Globe Newswire
Palisade Bio (PALI) Upgraded to Buy: What Does It Mean for the Stock?
3/7/2025 - Zacks Investment Research
Palisade Bio Participates in Virtual Investor What This Means Segment
3/4/2025 - Globe Newswire
Palisade Bio receives cash proceeds from Canada's SR&ED tax incentive program
2/20/2025 - The Fly
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)
2/20/2025 - Globe Newswire
Palisade Bio, Inc. Participates in the Virtual Investor Top 5 for '25 On-Demand Conference
2/19/2025 - Globe Newswire
Armistice Capital, LLC's Strategic Acquisition of Palisade Bio Inc Shares
2/15/2025 - GuruFocus
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis
2/10/2025 - GuruFocus
Palisade Bio presents preclinical data of PALI-2108
2/10/2025 - The Fly
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis
2/10/2025 - Globe Newswire
Head-To-Head Review: Palisade Bio (NASDAQ:PALI) & Protara Therapeutics (NASDAQ:TARA)
2/8/2025 - Ticker Report
Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress
1/29/2025 - GuruFocus
Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress
1/29/2025 - Globe Newswire
Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
1/22/2025 - GuruFocus
Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
1/22/2025 - Globe Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$14.86M
EBIT (TTM)
-$14.86M
Net Income (TTM)
-$14.44M
Balance Sheet
Total Assets (Q)
$10.88M
Total Debt (Q)
$169.00K
Total Liabilities (Q)
$3.39M
Book Value Per Share (Q)
$2.71
Cash Flow
Cash from Operations (TTM)
-$12.19M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$9.58M
Net Change in Cash (TTM)
-$2.61M
Filings
Filing Date
Monday, March 24, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
0.12
7-Day Total Return
4.96%
30-Day Total Return
-11.52%
60-Day Total Return
-44.44%
90-Day Total Return
-58.93%
Year to Date Total Return
-59.38%
1-Year Total Return
-87.77%
2-Year Total Return
-96.97%
3-Year Total Return
-99.87%
5-Year Total Return
--
52-week Low
Apr 04, 2025 - $0.60
52-week High
May 01, 2024 - $9.09
Valuation
Market Cap
$3.41M - Nano Cap
Enterprise Value
-$6.25M
Price/Sales (TTM)
--
Price/Book (Q)
0.29
Dividends and Shares
Shares Outstanding
2.16M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.palisadebio.com
Phone Number
858 704 4900
Address
7750 El Camino Real
Carlsbad, CA 92009
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases... more
NASDAQ 04/29/2025 3:31PM Eastern Quotes delayed